Radiopharmaceutical · Cytotoxic · developed by Cellectar Biosciences
Iodine I 125 iopofosine is a radioconjugate of iopofosine, a phospholipid ether analog labeled with the Auger-emitting isotope iodine I 125. It selectively accumulates in tumor cells that have increased membrane lipid rafts, enters the cells and travels to the nucleus, where it causes DNA double-strand breaks. It is being studied in breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07311993 | Phase 1 | Breast Cancer | Recruiting | CLRB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast Cancer
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLRB page.
See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLRB catalysts and pipeline →